News & Updates

Testosterone offers no long-distance mobility benefit to women with hip fracture

Use of topical testosterone therapy in addition to supervised exercise training does little to improve long-distance walking ability for older women recovering from a hip fracture, according to the phase III STEP-HI randomized clinical trial.

Seladelpar improves cholestatic, liver injury markers in patients with PBC, cirrhosis

Treatment with seladelpar led to improvements in markers of cholestasis and liver injury in patients with primary biliary cholangitis (PBC) and compensated cirrhosis, according to an additional analysis of the RESPONSE trial presented at DDW 2025.

Etrasimod shows promise in eosinophilic oesophagitis

In the treatment of eosinophilic oesophagitis, the use of etrasimod is well tolerated and results in sustained histological and endoscopic improvements and symptom reduction, according to the results of a phase II study.

Monitor kidney function to reduce CV risk in CKD patients: study

In patients with stable chronic kidney disease (CKD), the risk of cardiomyopathy caused by kidney disease appears to be greater than the risk of CKD progression due to heart disease, suggests a study, noting that these observational analyses do not establish causality.

High, increasing BMI ups risk of adulthood OSA

Individuals with high or continuously increasing BMI from childhood to middle age are at greater risk of developing obstructive sleep apnoea (OSA) later in life, reveals a study.

Why Combine? Addressing the Gap for Blood Pressure Control

Investigational Gal3 inhibitor NAVIGATEs MASH treatment field

The galectin-3 (Gal3) inhibitor belapectin, given at the established 2-mg dose, demonstrates its treatment potential for metabolic dysfunction-associated steatohepatitis (MASH) cirrhosis and portal hypertension (PH) in the phase IIb/III NAVIGATE trial.

Personalizing upfront treatment options for advanced EGFRm NSCLC

This article will summarize the latest developments in the first-line management of advanced EGFRm NSCLC and highlight key consideration factors.